Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
This study was performed to determine whether a new F18-FDS (fluorodeoxysorbitol) PET (Positron emission tomography) can replace nuclear medicine renal scintigraphy as an image evaluation method for renal function. In comparison with Tc99m-DTPA used for clinical renal scintigraphy, the blood clearance of F18-FDS in normal rats was slightly slower, but it was considered not to affect imaging evaluation. Then, we evaluated the renal function of renal disease rat models (unilateral ureteral obstruction and glycerol-induced acute renal failure) using F18-FDS PET images. F18-FDS PET showed a three-dimensional image of impaired kidney function, which is difficult to image by Tc99m-DTPA renal scintigraphy. These findings confirmed that F18-FDS PET could evaluate renal disease.
|